Target intelligence / Profile preview

Proto-oncogene protein c-mdmx (MDMX)

Target: MDMX
Molecular classification: E3 ubiquitin ligase regulator, Transcription factor regulator

Overview

MDMX (also known as MDM4) is a key negative regulator of the tumor suppressor p53. It inhibits p53's transcriptional activity by binding to its transactivation domain. MDMX cooperates with MDM2 to promote p53 degradation and has p53-independent oncogenic functions. Overexpression of MDMX is observed in various cancers, making it a therapeutic target for reactivating p53.

Other names: MDM4

Mechanism of action

Inhibition of MDMX-p53 interaction, promotion of p53 activity, dual inhibition of MDMX/MDM2

Biological functions

Negative regulation of TP53 transcriptional activityRegulation of apoptosisCell cycle regulation

Disease associations

Cancer

Safety considerations

Potential for off-target effectsDevelopment of resistance

Beyond the preview

Go deeper on Proto-oncogene protein c-mdmx (MDMX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proto-oncogene protein c-mdmx (MDMX).

Explore the full profile